<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE ep-patent-document SYSTEM "ep-patent-document-v1-4.dtd">
<ep-patent-document id="EP1459743A8" country="EP" dtd-version="ep-patent-document-v1-4.dtd" doc-number="1459743" date-publ="20050202" file="04014078.2" lang="en" kind="A8" status="c"><SDOBI lang="en"><B000><eptags><B001EP>ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYAL..............................</B001EP><B005EP>J</B005EP><B007EP>DIM350 (Ver 2.1 Jan 2001)  1990850/0 1999001/0</B007EP><B053EP>This application was filed on 16 - 06 - 2004 as a divisional application to the application mentioned under INID code 62.</B053EP></eptags></B000><B100><B110>1459743</B110><B120><B121>CORRECTED EUROPEAN PATENT APPLICATION</B121></B120><B130>A8</B130><B132EP>A2</B132EP><B140><date>20050202</date></B140><B150><B151>W1</B151><B153>72</B153><B155><B1551>DE</B1551><B1552>Bibliographie</B1552><B1551>EN</B1551><B1552>Bibliography</B1552><B1551>FR</B1551><B1552>Bibliographie</B1552></B155></B150><B190>EP</B190></B100><B200><B210>04014078.2</B210><B220><date>19990813</date></B220><B250>En</B250><B251EP>En</B251EP><B260>En</B260></B200><B300><B310>24776298</B310><B320><date>19980817</date></B320><B330><ctry>JP</ctry></B330><B310>12296099</B310><B320><date>19990428</date></B320><B330><ctry>JP</ctry></B330></B300><B400><B405><date>20050202</date><bnum>200505</bnum></B405><B430><date>20040922</date><bnum>200439</bnum></B430><B480><date>20050202</date><bnum>200505</bnum></B480></B400><B500><B510><B516>7</B516><B511> 7A 61K  31/00   A</B511><B512> 7A 61K  31/437  B</B512><B512> 7A 61K  31/4409 B</B512><B512> 7A 61K  31/4545 B</B512><B512> 7A 61K  31/496  B</B512><B512> 7A 61K  31/551  B</B512><B512> 7A 61P  27/06   B</B512></B510><B540><B541>de</B541><B542>Verbindung zur Vorbeugung und Behandlung von Glaukoma</B542><B541>en</B541><B542>Agent for prophylaxis and treatment of glaucoma</B542><B541>fr</B541><B542>Agent pour prévenir et traiter le glaucome</B542></B540><B590><B598>NONE</B598></B590></B500><B600><B620><parent><pdoc><dnum><anum>99937073.7</anum><pnum>1034793</pnum></dnum><date>19990813</date></pdoc></parent></B620></B600><B700><B710><B711><snm>Senju Pharmaceutical Co., Ltd.</snm><iid>00697371</iid><irf>041421ep/AvK/su</irf><adr><str>5-8, Hiranomachi 2-chome, Chuo-Ku</str><city>Osaka-shi, Osaka 541-0046</city><ctry>JP</ctry></adr></B711><B711><snm>Mitsubishi Pharma Corporation</snm><iid>03099353</iid><irf>041421ep/AvK/su</irf><adr><str>6-9, Hiranomachi 2-chome, Chuo-ku</str><city>Osaka-shi, Osaka 541-0046</city><ctry>JP</ctry></adr></B711></B710><B720><B721><snm>Azuma, Mitsuyoshi</snm><adr><str>4-13-102, Manchidani-cho</str><city>Nishinomiya-shi Hyogo 662-0031</city><ctry>JP</ctry></adr></B721><B721><snm>Yoshida, Yukuo</snm><adr><str>6-3, Kouyou-cho 3-chome Kita-ku</str><city>Kobe-shi Hyogo 651-1203</city><ctry>JP</ctry></adr></B721><B721><snm>Waki, Mitsunori</snm><adr><str>8-16, Waidori, Nishi-ku</str><city>Kobe-shi Hyogo 651-2120</city><ctry>JP</ctry></adr></B721><B721><snm>Uehata, Masayoshi, c/o Mitsubishi Pharma Corp.</snm><adr><str>6-9 Hiranomachi 2-chome, Chuo-ku</str><city>Osaka-shi, Osaka 541-0046</city><ctry>JP</ctry></adr></B721></B720><B740><B741><snm>von Kreisler, Alek, Dipl.-Chem.</snm><sfx>et al</sfx><iid>00012439</iid><adr><str>Patentanwälte, von Kreisler-Selting-Werner, Deichmannhaus am Dom, Bahnhofsvorplatz 1</str><city>50667 Köln</city><ctry>DE</ctry></adr></B741></B740></B700><B800><B840><ctry>AT</ctry><ctry>BE</ctry><ctry>CH</ctry><ctry>CY</ctry><ctry>DE</ctry><ctry>DK</ctry><ctry>ES</ctry><ctry>FI</ctry><ctry>FR</ctry><ctry>GB</ctry><ctry>GR</ctry><ctry>IE</ctry><ctry>IT</ctry><ctry>LI</ctry><ctry>LU</ctry><ctry>MC</ctry><ctry>NL</ctry><ctry>PT</ctry><ctry>SE</ctry></B840><B844EP><B845EP><ctry>AL</ctry></B845EP><B845EP><ctry>LT</ctry></B845EP><B845EP><ctry>LV</ctry></B845EP><B845EP><ctry>MK</ctry></B845EP><B845EP><ctry>RO</ctry></B845EP><B845EP><ctry>SI</ctry></B845EP></B844EP></B800></SDOBI><abstract id="abst" lang="en"><p id="p0001" num="0001">An agent for the prophylaxis and treatment of glaucoma, which contains a compound having a Rho kinase inhibitory activity, particularly an agent for the prophylaxis and treatment of glaucoma, which contains a compound of the formula (I)<img id="" file="80000001.TIF" he="18" wi="75" img-content="chem" img-format="tif" orientation="portrait" inline="no"/> wherein each symbol is as defined in the specification, as the compound having a Rho kinase inhibitory activity, is provided. The agent for the prophylaxis and treatment of glaucoma of the present invention is a novel agent for the prophylaxis and treatment of glaucoma and has intraocular pressure lowering action, optic disc blood flow improving action and aqueous humor outflow promoting action.</p></abstract></ep-patent-document>
